GSK3B

Overview

Glycogen synthase kinase 3β (GSK3β) is a serine/threonine protein kinase with broad roles in cell signaling, metabolism, and stress-response pathways. It is one of two closely related GSK3 isoforms and is widely studied because of its involvement in phosphorylation-dependent regulation of proteins that influence neuronal function, inflammatory signaling, and metabolic homeostasis. In biomedical research, GSK3β is often discussed as a signaling hub rather than a single-pathway enzyme, since its activity can intersect with pathways such as AMPK/mTOR, β-catenin-related signaling, and kinase networks involving Protein Kinase C Alpha (PKCα).

Because of this central position, GSK3β has attracted attention as a therapeutic target in neurodegenerative disease, cancer-related signaling, and metabolic disorders. In the recent studies summarized here, it was investigated in contexts ranging from Alzheimer’s disease-related pathology, including tau and Amyloid beta (Aβ)-associated mechanisms, to endothelial dysfunction in Metabolic dysfunction associated steatohepatitis (MASH). These studies reinforce the view that GSK3β can influence both neuronal and vascular disease processes through phosphorylation-dependent control of downstream targets.

Recent Publications Summary

GSK3β emerged as a critical therapeutic target in neurodegenerative and cognitive disorders, particularly Alzheimer's disease and tauopathies. Computational pipelines successfully identified novel brain-penetrant GSK-3β inhibitors through pharmacophore screening, molecular docking, and blood–brain barrier filtering 42493523Jul. Direct GSK3β inhibition or genetic knockdown ameliorated cognitive dysfunction, synaptic damage, and mitochondrial dysfunction in sporadic Alzheimer's disease-like models, primarily by restoring Wnt/β-catenin signaling and glucose metabolism 42307791Jun. Multiple therapeutic modalities targeted GSK-3β to address tau hyperphosphorylation: amino-pyrazole-based multikinase inhibitors simultaneously inhibited GSK-3β, FYN, and DYRK1A with superior efficacy compared to single-target approaches 42054438Apr, while coumarin derivatives inhibited GSK-3β alongside acetylcholinesterase and butyrylcholinesterase activities 41691754Feb. A highly potent GSK-3β inhibitor (compound 3c, IC50 = 0.66 nM) also chelated pathogenic metal ions, suppressed amyloid-β accumulation, and promoted neurite outgrowth 41855636Mar. Isoorientin and natural product mixtures like icariin, astragaloside IV, and puerarin ameliorated cognitive dysfunction in diabetic models through GSK3β/Nrf2 and GSK-3β/PGC-1α axes, respectively 42467274Jul41934898Apr.

GSK3β regulated glucose homeostasis and metabolic complications across multiple organ systems. In diabetic myocardial fibrosis, nicotinamide mononucleotide amplified SIRT3-mediated deacetylation of GSK3β to suppress Smad3 phosphorylation and reduce fibrosis markers 42573891Aug. The alkaloid cistanoside A decreased tau hyperphosphorylation and neuronal apoptosis through AKT/GSK3β pathway modulation in Alzheimer's disease models 42423799Jul. In diabetic nephropathy, inotodiol activated the PI3K/Akt/GSK-3β pathway to restore podocyte function, reduce oxidative stress, and ameliorate renal damage 42367005Jun. metformin attenuated age-related ciliary muscle senescence by downregulating GSK-3β, stabilizing β-catenin, and relieving cell-cycle arrest 42118039May. The β-adrenergic agonist isoprenaline protected against diabetic kidney disease through multi-target regulation of the cGAS-STING pathway, including GSK3β modulation 41795784Mar.

GSK3β regulated immune resistance and inflammation in cancer and metabolic contexts. In anti-PD-1-refractory tumors, protein kinase C inhibition overcame immune resistance by activating GSK3β, which promoted PD-L1 degradation and enhanced CD8+ T cell recruitment 42234523Jun. Network pharmacology identified GSK3B as a prognostic target in triple-negative breast cancer, with molecular docking demonstrating high-affinity binding of Schisandrin A 42220063Jun. Aurora Kinase A-mediated radioresistance in pancreatic ductal adenocarcinoma operated through direct GSK3β interaction, enabling phosphorylation and inactivation of the tumor suppressor PTEN 41864259Mar. In metabolic dysfunction-associated steatohepatitis, endothelial GSK3β promoted lipotoxic endotheliopathy by enhancing dendritic cell maturation and hepatic immune infiltration 42084928May. GSK3β also participated in ferroptosis suppression in osteoarthritis, where engineered mesenchymal stem cell-derived exosomes delivered miR-142a-3p to target the GSK3β/Nrf2/SLC7A11 axis 41637927Feb.

Ischemia-reperfusion injury and cardioprotection highlighted GSK3β as a nodal point in survival signaling. Nuciferine ameliorated cerebral ischemia-reperfusion injury by activating the phosphatidylinositol 3-kinase/protein kinase B/glycogen synthase kinase 3 beta pathway to suppress mitochondrial permeability transition pore opening and apoptosis 42172986May. Vagal nerve stimulation-induced early and delayed cardioprotection against myocardial ischemia involved GSK-3β phosphorylation alongside protein kinase B activation 41803481Mar. Collectively, these studies position GSK3β as a convergence point for therapeutic intervention across neurodegenerative, metabolic, cardiac, malignant, and inflammatory pathologies, with both inhibition and phosphorylation-based inactivation emerging as complementary therapeutic strategies.

What Changes, What Holds

1. Natural product-derived and engineered GSK-3β inhibitors engage Nrf2 and PGC-1α axes, revealing metabolic pathway intersections beyond those established in the Overview
NEW DIRECTION Isoorientin, icariin, astragaloside IV, and puerarin ameliorate cognitive dysfunction in diabetic models through GSK3β/Nrf2 and GSK-3β/PGC-1α pathway modulation 42467274Jul41934898Apr, identifying metabolic regulators not specified in the baseline's description of GSK-3β's pathway intersections. A potent inhibitor with metal-chelating properties simultaneously suppresses amyloid-β and promotes neurite outgrowth 41855636Mar. Multikinase inhibition targeting GSK-3β alongside FYN and DYRK1A outperforms single-target compounds 42054438Apr, though this remains within the neurodegenerative domain the baseline anticipates.

2. GSK-3β regulates metabolic disease across multiple organ systems including cardiac, renal, and ocular tissues
NEW DIRECTION Diabetic myocardial fibrosis, nephropathy, age-related ciliary muscle senescence, and kidney disease each exhibit GSK-3β-dependent pathogenic mechanisms amenable to therapeutic targeting 42573891Aug42118039May, extending GSK-3β's clinical relevance far beyond the neurological and MASH-specific endothelial contexts the Overview emphasizes. Multiple signaling cascades—SIRT3 deacetylation, AKT/GSK3β modulation, β-catenin stabilization—converge on GSK-3β as a regulatory hub in systemic metabolic complications affecting cardiovascular, renal, and ocular systems.

3. GSK-3β regulates cancer immunotherapy response through PD-L1 degradation and ferroptosis suppression, establishing new functional roles in immune evasion and ferroptotic cell death
NEW DIRECTION Anti-PD-1-refractory tumors overcome immune resistance when PKC inhibition activates GSK3β, driving PD-L1 degradation and CD8+ T cell recruitment 42234523Jun—a checkpoint regulatory role absent from the Overview's cancer-related signaling discussion. MSC-derived exosomes carrying miR-142a-3p suppress ferroptosis in osteoarthritis through the GSK3β/Nrf2/SLC7A11 axis 41637927Feb, revealing a new cytoprotective function for GSK-3β in iron-dependent cell death beyond the neurodegenerative and metabolic disease domains covered in the baseline.

4. GSK-3β phosphorylation-mediated inactivation provides cardioprotection in ischemia-reperfusion injury through pathway activation, distinct from direct enzyme inhibition
NEW DIRECTION Nuciferine and vagal nerve stimulation activate PI3K/PKB cascades leading to GSK-3β phosphorylation and inactivation, suppressing mitochondrial apoptosis in cerebral ischemia-reperfusion injury 42172986May and providing myocardial protection 41803481Mar. In contrast to the Overview's positioning of GSK-3β as a therapeutic target in neurodegenerative and metabolic disease, this indirect inactivation strategy through upstream pathway engagement represents a pharmacologically distinct approach expanding GSK-3β's clinical relevance to acute ischemic injury contexts.

Overview update candidates: GSK-3β's multi-organ involvement in metabolic complications (cardiac; renal; ocular); its regulation of PD-L1 and immune checkpoint degradation in cancer; its interaction with metabolic regulators Nrf2 and PGC-1α; and cardioprotection through pathway-mediated phosphorylation in ischemia-reperfusion injury.